# Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

> **NCT01651949** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 2520 (actual)

## Conditions studied

- Genital Warts
- Anal Cancer
- Anal Intraepithelial Neoplasia

## Interventions

- **BIOLOGICAL:** 9vHPV Vaccine

## Key facts

- **NCT ID:** NCT01651949
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-29
- **Primary completion:** 2014-08-04
- **Final completion:** 2014-08-04
- **Target enrollment:** 2520 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01651949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01651949, "Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01651949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*